No one seems eager to defend the QALY tool as a House Republican bill seeks to prohibit any federal agency from using Quality Adjusted Life Years as a formula to determine pricing.
An early health care priority for the new Republican leadership of the House Energy and Commerce Committee is a seemingly unlikely effort to prohibit federal agencies from using Quality Adjusted Life Years (QALYs) in any cost effectiveness activity.
The Health Subcommittee marked-up a bill (HR 485) 8 March that would take a section of law prohibiting the...
The US Medicare Payment Advisory Commission worries that Medicare prescription drug market trends may cause the stand-alone plan portion of the program to “wither away,” which could take the traditional fee-for-service side of Medicare with it.
The US MFN executive order is the latest in a series of concerning US developments that are contributing to uncertainty for the European pharmaceutical industry, according to France Biotech’s vice president, Alexandre Regniault.
Japan is cutting more drug reimbursement prices following cost effectiveness analysis and is applying the methodology to a new group of products including Wegovy and Leqembi.
